
Opdivo® Approved in South Korea for First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino) announced today that its Korean subsidiary, Ono Pharma Korea Co., Ltd. (OPKR), received additional approval from South Korea’s Ministry of Food and Drug Safety (MFDS) on July 17. The approval…











